Qureight

Headquartered in Cambridge, UK, Qureight’s data and AI-analytics platform accelerates drug development in lung and heart diseases. It houses a cloud-based, vendor-agnostic platform which holds ISO 13485 and ISO 27001 accreditation. The team is led by co-founder & CEO Dr Muhunthan Thillai, a pulmonologist specialising in complex lung diseases.

Content by Qureight

Abstract digital visualization of artificial intelligence data processing.

| 2 min read

byQureight

Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion

Qureight’s deep-learning image biomarkers and clinical data analytics platform used to analyse enrolled idiopathic pulmonary fibrosis (IPF) patient data, supporting efficacy outcome and expansion to larger global patient studies

Industry Perspectives

AI image simulation of a human lung created from historic imaging data

| 3 min read

byQureight

Qureight’s synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment

AI-enabled analytics platform demonstrates how real-world data used in place of human placebo and control groups can significantly reduce study costs and duration

Industry Perspectives

Page 1 of 1 - 2 Total Items

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.

Automating the counting of 3D cell cultures

Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.

Webinars

Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.

Imaging neural activity in action

Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.

Infographics

Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.

Building complex in vitro models to support new approach methodologies

As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?